GeNeuro SA
EPA:GNRO.PA
Overview | Financials
Company Name | GeNeuro SA |
Symbol | GNRO.PA |
Currency | EUR |
Price | 0.077 |
Market Cap | 2,276,362 |
Dividend Yield | 0% |
52-week-range | 0.056 - 2.35 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jesus Martin-Garcia |
Website | https://www.geneuro.com |
An error occurred while fetching data.
About GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD